Medicina
Departamento
Kyoto University
Kioto, JapónPublicaciones en colaboración con investigadores/as de Kyoto University (27)
2023
-
A second update on mapping the human genetic architecture of COVID-19
Nature
-
Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial
The Lancet Oncology, Vol. 24, Núm. 1, pp. 77-90
-
Author Correction: Optical coherence tomography in coronary atherosclerosis assessment and intervention (Nature Reviews Cardiology, (2022), 19, 10, (684-703), 10.1038/s41569-022-00687-9)
Nature Reviews Cardiology
-
Machine learning to predict major bleeding during anticoagulation for venous thromboembolism: possibilities and limitations
British Journal of Haematology, Vol. 201, Núm. 5, pp. 971-981
2022
-
Cost-effectiveness of palbociclib in early breast cancer patients with a high risk of relapse: Results from the PENELOPE-B trial
Frontiers in Oncology, Vol. 12
-
Effects of capecitabine as part of neo-/adjuvant chemotherapy – A meta-analysis of individual breast cancer patient data from 13 randomised trials including 15,993 patients
European Journal of Cancer, Vol. 166, pp. 185-201
-
Novel genes and sex differences in COVID-19 severity
Human molecular genetics, Vol. 31, Núm. 22, pp. 3789-3806
-
Optical coherence tomography in coronary atherosclerosis assessment and intervention
Nature Reviews Cardiology, Vol. 19, Núm. 10, pp. 684-703
2021
-
Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer-The Penelope-B Trial
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 39, Núm. 14, pp. 1518-1530
-
Spontaneous ARIA-like events in cerebral amyloid angiopathy–related inflammation a multicenter prospective longitudinal cohort study
Neurology, Vol. 97, Núm. 18, pp. E1809-E1822
-
The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group
npj Breast Cancer, Vol. 7, Núm. 1
2020
-
Derivation and validation of a clinical prediction rule for thrombolysis-associated major bleeding in patients with acute pulmonary embolism: The BACS score
European Respiratory Journal, Vol. 56, Núm. 6
-
Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial
The Lancet Oncology, Vol. 21, Núm. 12, pp. 1574-1588
-
Health-Related Quality of Life in MONARCH 3: Abemaciclib plus an Aromatase Inhibitor as Initial Therapy in HR+, HER2− Advanced Breast Cancer
Oncologist, Vol. 25, Núm. 9, pp. e1346-e1354
2019
-
Correction to: Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer (BMC Cancer (2019) 19 (517) DOI: 10.1186/s12885-019-5687-0)
BMC Cancer
-
MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer
npj Breast Cancer, Vol. 5, Núm. 1
-
Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer
BMC Cancer, Vol. 19, Núm. 1
-
Trastuzumab emtansine with or without pertuzumab versus trastuzumab with taxane for human epidermal growth factor receptor 2–positive advanced breast cancer: Final results from MARIANNE
Cancer, Vol. 125, Núm. 22, pp. 3974-3984
2018
2017
-
De-escalating and escalating treatments for early-stage breast cancer: The St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017
Annals of Oncology, Vol. 28, Núm. 8, pp. 1700-1712